Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home
Nov 12, 2019
1 min read
Updated: Sep 13, 2022
Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans
Really enjoyed reading this post. The explanation of how strategic investments and research partnerships can shape the future of healthcare was very informative. It’s interesting to see how companies make long-term decisions through innovation and collaboration. I goprogaragedoorrepair.com recently came across a similar discussion on a Texas-based review blog and it also highlighted the value of thoughtful business decisions.
I played Block Blast while waiting for the train conductor to check my ticket. He reached my seat just as I cleared another row.